Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Geron Corp (GERN)
since 2006 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Geron Corp.
Table 2 shows the detailed insider transactions.
This company's CIK number is 886744.
Total stock buying since 2006: $773,609.
Total stock sales since 2006: $25,594,819.
Total stock option exercises since 2006: $9,282,124.
Table 3. Detailed insider trading at Geron Corp (GERN)
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2025-02-27 | Ziegler James (EVP, Chief Commercial Officer) | Buy | 100,000 | 1.60 | 160,000 |
| 2025-02-27 | Samuels Scott Alan (EVP, Chief Legal Officer) | Buy | 15,000 | 1.61 | 24,150 |
| 2025-02-27 | Scarlett John A (Chairman, President and CEO) | Buy | 12,500 | 1.76 | 22,062 |
| 2024-07-08 | Grethlein Andrew J (EVP, Chief Operating Officer) | Sale | 674,348 | 4.56 | 3,073,003 |
| 2024-07-08 | Grethlein Andrew J (EVP, Chief Operating Officer) | Option Ex | 674,348 | 1.72 | 1,159,878 |
| 2024-06-10 | Feller Faye (EVP, Chief Medical Officer) | Sale | 287,900 | 4.63 | 1,334,128 |
| 2024-06-10 | Feller Faye (EVP, Chief Medical Officer) | Option Ex | 287,900 | 1.14 | 327,630 |
| 2024-06-10 | Kapur Anil (EVP, Corp Strategy & CCO) | Sale | 421,875 | 4.64 | 1,959,609 |
| 2024-06-10 | Kapur Anil (EVP, Corp Strategy & CCO) | Option Ex | 421,875 | 1.06 | 447,187 |
| 2023-08-24 | O'farrell Elizabeth G. (Director) | Buy | 13,186 | 2.28 | 30,064 |
| 2023-05-11 | Lawlis V Bryan (Director) | Sale | 35,000 | 3.00 | 105,000 |
| 2023-05-11 | Lawlis V Bryan (Director) | Option Ex | 35,000 | 1.10 | 38,500 |
| 2023-05-01 | Molineaux Susan (Director) | Sale | 35,000 | 2.48 | 86,800 |
| 2023-05-01 | Molineaux Susan (Director) | Option Ex | 35,000 | 1.10 | 38,500 |
| 2023-02-10 | Scarlett John A (Chairman, President and CEO) | Sale | 446,668 | 3.00 | 1,340,004 |
| 2023-02-10 | Scarlett John A (Chairman, President and CEO) | Option Ex | 446,668 | 1.50 | 670,002 |
| 2023-02-09 | Scarlett John A (Chairman, President and CEO) | Sale | 446,666 | 3.03 | 1,353,397 |
| 2023-02-09 | Scarlett John A (Chairman, President and CEO) | Option Ex | 446,666 | 1.50 | 669,999 |
| 2023-02-09 | Grethlein Andrew J (EVP, Chief Operating Officer) | Sale | 384,719 | 3.03 | 1,165,698 |
| 2023-02-09 | Grethlein Andrew J (EVP, Chief Operating Officer) | Option Ex | 150,000 | 1.51 | 226,500 |
| 2023-02-08 | Bloom Olivia Kyusuk (EVP, Chief Financial Officer) | Sale | 400,000 | 3.08 | 1,232,000 |
| 2023-02-08 | Bloom Olivia Kyusuk (EVP, Chief Financial Officer) | Option Ex | 400,000 | 1.51 | 604,000 |
| 2023-02-08 | Scarlett John A (Chairman, President and CEO) | Sale | 446,666 | 3.08 | 1,375,731 |
| 2023-02-08 | Scarlett John A (Chairman, President and CEO) | Option Ex | 446,666 | 1.50 | 669,999 |
| 2023-01-13 | Eastham Karin (Director) | Option Ex | 35,000 | 1.10 | 38,500 |
| 2022-09-12 | Grethlein Andrew J (EVP, Chief Operating Officer) | Option Ex | 234,719 | 1.70 | 399,022 |
| 2022-04-20 | Eastham Karin (Director) | Option Ex | 35,000 | 1.41 | 49,350 |
| 2020-08-21 | O'farrell Elizabeth G. | Buy | 17,441 | 1.73 | 30,172 |
| 2020-01-10 | O'farrell Elizabeth G. (Director) | Buy | 3,000 | 1.34 | 4,035 |
| 2019-04-09 | Behrs Melissa Kelly (EVP, Chief Business Officer) | Sale | 120,635 | 2.00 | 241,270 |
| 2018-09-13 | Spiegel Robert J. (Director) | Sale | 175,000 | 6.85 | 1,198,750 |
| 2018-09-13 | Spiegel Robert J. (Director) | Option Ex | 175,000 | 3.26 | 570,500 |
| 2018-08-24 | Rosenfield Stephen (EVP, Genl Counsel & Secretary) | Sale | 1,362,250 | 4.51 | 6,143,747 |
| 2018-08-24 | Rosenfield Stephen (EVP, Genl Counsel & Secretary) | Option Ex | 1,362,250 | 2.06 | 2,806,235 |
| 2015-05-29 | Bloom Olivia Kyusuk (EVP, Chief Financial Officer) | Sale | 2,380 | 3.84 | 9,139 |
| 2015-05-29 | Behrs Melissa Kelly (EVP BD and Port&Alliance Mgmt) | Sale | 2,380 | 3.84 | 9,139 |
| 2015-03-18 | Hofstaetter Thomas (Director) | Sale | 70,000 | 4.10 | 287,000 |
| 2015-03-18 | Hofstaetter Thomas (Director) | Option Ex | 70,000 | 1.25 | 87,849 |
| 2014-05-29 | Bloom Olivia Kyusuk (EVP, Chief Financial Officer) | Sale | 3,379 | 2.10 | 7,095 |
| 2014-05-29 | Behrs Melissa Kelly (EVP Portfolio & Alliance Mgmt) | Sale | 4,826 | 2.10 | 10,134 |
| 2014-05-09 | Bradbury Daniel (Director) | Buy | 142,776 | 1.75 | 249,858 |
| 2014-04-01 | Bloom Olivia Kyusuk (EVP, Chief Financial Officer) | Sale | 7,435 | 2.13 | 15,836 |
| 2014-04-01 | Behrs Melissa Kelly (EVP Portfolio & Alliance Mgmt) | Sale | 12,310 | 2.13 | 26,220 |
| 2013-04-01 | Scarlett John A (President and CEO) | Buy | 50,000 | 1.03 | 51,500 |
| 2013-01-17 | Behrs Melissa Kelly (SVP Alliance and Prog Mgmt) | Sale | 28,292 | 1.65 | 46,568 |
| 2012-05-30 | Bloom Olivia Kyusuk (VP, Chief Acctg Officer) | Sale | 11,029 | 1.37 | 15,109 |
| 2012-05-30 | Kelsey Stephen Michael (EVP, R&D Head, CMO) | Sale | 9,300 | 1.37 | 12,741 |
| 2012-05-30 | Behrs Melissa Kelly (SVP Strategic Portfolio Mgmt) | Sale | 18,910 | 1.37 | 25,906 |
| 2012-05-30 | Earp David (SVP, Corp Transactions) | Sale | 27,155 | 1.37 | 37,202 |
| 2011-11-22 | Kiley Thomas (Director) | Buy | 64,275 | 1.56 | 100,269 |
| 2011-10-05 | Kiley Thomas (Director) | Buy | 50,000 | 2.03 | 101,499 |
| 2011-06-14 | Bloom Olivia Kyusuk (VP, Chief Acctg Officer) | Sale | 6,997 | 4.28 | 29,947 |
| 2011-06-14 | Kelsey Stephen Michael (EVP, R&D Head, CMO) | Sale | 4,858 | 4.28 | 20,792 |
| 2011-06-14 | Spink Katharine E. (SVP Alliance Mgmt & Operations) | Sale | 22,591 | 4.28 | 96,689 |
| 2011-06-14 | Lebkowski Jane (SVP, Chief Scientific Officer) | Sale | 25,262 | 4.28 | 108,121 |
| 2011-06-14 | Behrs Melissa Kelly (SVP Strategic Portfolio Mgmt) | Sale | 25,262 | 4.28 | 108,121 |
| 2011-06-14 | Greenwood David (President, Interim CEO, CFO) | Sale | 34,005 | 4.28 | 145,541 |
| 2011-06-14 | Earp David (Chief Legal Counsel) | Sale | 25,262 | 4.28 | 108,121 |
| 2011-05-24 | Bloom Olivia Kyusuk (VP, Chief Acctg Officer) | Sale | 1,200 | 4.47 | 5,364 |
| 2011-05-24 | Spink Katharine E. (SVP Prgm Mgmt, Cell Therapies) | Sale | 419 | 4.47 | 1,872 |
| 2011-05-24 | Lebkowski Jane (SVP, Chief Scientific Officer) | Sale | 2,975 | 4.47 | 13,298 |
| 2011-05-24 | Behrs Melissa Kelly (SVP Strategic Portfolio Mgmt) | Sale | 2,975 | 4.47 | 13,298 |
| 2011-05-24 | Greenwood David (President, Interim CEO, CFO) | Sale | 4,462 | 4.47 | 19,945 |
| 2011-05-24 | Earp David (SVP Bus Dev, Chief Patnt Couns) | Sale | 2,975 | 4.47 | 13,298 |
| 2011-05-05 | Kelsey Stephen Michael (EVP, CMO, Oncology) | Sale | 14,163 | 4.83 | 68,407 |
| 2010-06-02 | Spink Katharine E. (VP Operations, Regen Med Progs) | Sale | 8,186 | 5.43 | 44,449 |
| 2010-06-02 | Okarma Thomas (President and CEO) | Sale | 18,874 | 5.43 | 102,485 |
| 2010-06-02 | Lebkowski Jane (SVP, CSO Regen Med) | Sale | 10,617 | 5.43 | 57,650 |
| 2010-06-02 | Behrs Melissa Kelly (SVP Oncology) | Sale | 10,617 | 5.43 | 57,650 |
| 2010-06-02 | Greenwood David (EVP and CFO) | Sale | 14,746 | 5.43 | 80,070 |
| 2010-06-02 | Earp David (SVP Bus Dev, Chief Patnt Couns) | Sale | 10,617 | 5.43 | 57,650 |
| 2010-05-24 | Spink Katharine E. (VP Operations, Regen Med Progs) | Sale | 385 | 5.11 | 1,967 |
| 2010-05-24 | Okarma Thomas (President and CEO) | Sale | 4,671 | 5.11 | 23,868 |
| 2010-05-24 | Lebkowski Jane (SVP, CSO Regen Med) | Sale | 2,336 | 5.11 | 11,936 |
| 2010-05-24 | Behrs Melissa Kelly (SVP Oncology) | Sale | 2,336 | 5.11 | 11,936 |
| 2010-05-24 | Greenwood David (EVP and CFO) | Sale | 3,503 | 5.11 | 17,900 |
| 2010-05-24 | Earp David (SVP Bus Dev, Chief Patnt Couns) | Sale | 2,336 | 5.11 | 11,936 |
| 2010-04-28 | Kelsey Stephen Michael (EVP, CMO, Oncology) | Sale | 3,707 | 5.66 | 20,981 |
| 2009-05-29 | Spink Katharine E. (VP Operations, Regen Med Progs) | Sale | 400 | 6.35 | 2,540 |
| 2009-05-29 | Benedetti Fabio M (SVP, Chief Med Off, Oncology) | Sale | 2,277 | 6.35 | 14,458 |
| 2009-05-29 | Okarma Thomas (President and CEO) | Sale | 5,828 | 6.35 | 37,007 |
| 2009-05-29 | Lebkowski Jane (SVP, CSO Regen Med) | Sale | 2,277 | 6.35 | 14,458 |
| 2009-05-29 | Behrs Melissa Kelly (SVP Oncology) | Sale | 2,277 | 6.35 | 14,458 |
| 2009-05-29 | Harley Calvin (VP, CSO Telomerase Tech) | Sale | 2,277 | 6.35 | 14,458 |
| 2009-05-29 | Greenwood David (EVP and CFO) | Sale | 3,416 | 6.35 | 21,691 |
| 2009-05-29 | Earp David (SVP Bus Dev, Chief Patnt Couns) | Sale | 2,277 | 6.35 | 14,458 |
| 2009-05-26 | Spink Katharine E. (VP Operations, Regen Med Progs) | Sale | 2,864 | 6.75 | 19,332 |
| 2009-05-26 | Okarma Thomas (President and CEO) | Sale | 46,669 | 6.75 | 315,015 |
| 2009-05-26 | Lebkowski Jane (SVP, CSO Regen Med) | Sale | 14,092 | 6.75 | 95,121 |
| 2009-05-26 | Behrs Melissa Kelly (SVP Oncology) | Sale | 6,819 | 6.75 | 46,028 |
| 2009-05-26 | Harley Calvin (VP, CSO Telomerase Tech) | Sale | 10,001 | 6.75 | 67,506 |
| 2009-05-26 | Greenwood David (EVP and CFO) | Sale | 19,320 | 6.75 | 130,410 |
| 2009-05-26 | Earp David (SVP Bus Dev, Chief Patnt Couns) | Sale | 15,456 | 6.75 | 104,328 |
| 2009-04-03 | Benedetti Fabio M (SVP, Chief Med Off, Oncology) | Sale | 5,195 | 4.44 | 23,065 |
| 2009-02-02 | Behrs Melissa Kelly (SVP Oncology) | Sale | 14,765 | 8.12 | 119,891 |
| 2009-01-30 | Walker John Peter (Director) | Sale | 48,617 | 8.28 | 402,548 |
| 2009-01-30 | Walker John Peter (Director) | Option Ex | 48,617 | 4.64 | 225,388 |
| 2009-01-29 | Harley Calvin (VP and CSO) | Sale | 30,489 | 7.11 | 216,776 |
| 2009-01-05 | Okarma Thomas (President and CEO) | Sale | 12,512 | 4.90 | 61,308 |
| 2009-01-05 | Lebkowski Jane (SVP Regen Medicine) | Sale | 8,861 | 4.90 | 43,418 |
| 2009-01-05 | Behrs Melissa Kelly (SVP Oncology) | Sale | 8,861 | 4.90 | 43,418 |
| 2009-01-05 | Harley Calvin (VP and CSO) | Sale | 8,861 | 4.90 | 43,418 |
| 2009-01-05 | Greenwood David (EVP and CFO) | Sale | 10,732 | 4.90 | 52,586 |
| 2009-01-05 | Earp David (SVP Bus Dev, Chief Patnt Couns) | Sale | 8,861 | 4.90 | 43,418 |
| 2008-11-05 | Behrs Melissa Kelly (SVP Oncology) | Sale | 23,845 | 4.05 | 96,572 |
| 2008-01-04 | Okarma Thomas (President and CEO) | Sale | 13,166 | 5.34 | 70,306 |
| 2008-01-04 | Lebkowski Jane (SVP Regen Medicine) | Sale | 8,911 | 5.34 | 47,584 |
| 2008-01-04 | Behrs Melissa Kelly (SVP Oncology) | Sale | 8,911 | 5.34 | 47,584 |
| 2008-01-04 | Harley Calvin (VP and CSO) | Sale | 8,911 | 5.34 | 47,584 |
| 2008-01-04 | Greenwood David (EVP and CFO) | Sale | 11,039 | 5.34 | 58,948 |
| 2008-01-04 | Earp David (SVP Bus Dev, Chief Patnt Couns) | Sale | 8,911 | 5.34 | 47,584 |
| 2007-11-12 | Greenwood David (EVP and CFO) | Sale | 4,000 | 7.20 | 28,800 |
| 2007-05-21 | Barkas Alexander E (Director) | Option Ex | 5,000 | 9.00 | 45,000 |
| 2007-05-18 | Harley Calvin (VP and CSO) | Sale | 30,000 | 9.18 | 275,310 |
| 2007-05-18 | Harley Calvin (VP and CSO) | Option Ex | 30,000 | 4.56 | 136,890 |
| 2006-04-28 | Barkas Alexander E (Director) | Option Ex | 29,411 | 2.04 | 59,998 |
| 2006-03-08 | Harley Calvin (Chief Scientific Officer) | Option Ex | 5,489 | 2.04 | 11,197 |
| 2006-01-09 | Okarma Thomas (President and CEO) | Sale | 12,320 | 8.56 | 105,459 |
| 2006-01-09 | Lebkowski Jane (SVP, Regenerative Me) | Sale | 10,676 | 8.56 | 91,386 |
| 2006-01-09 | Behrs Melissa Kelly (VP, Oncology) | Sale | 8,441 | 8.56 | 72,254 |
| 2006-01-09 | Harley Calvin (Chief Scientific Officer) | Sale | 9,183 | 8.56 | 78,606 |
| 2006-01-09 | Greenwood David (Executive VP and CFO) | Sale | 12,183 | 8.56 | 104,286 |
| 2006-01-09 | Earp David (SVP Bus Dev / Chf Pa) | Sale | 11,323 | 8.56 | 96,924 |
Insider trading activities including stock purchases, stock sales, and option exercises
of GERN listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Geron Corp (symbol GERN,
CIK number 886744) see
the Securities and Exchange Commission (SEC) website.